Karuna Therapeutics Inc (Karuna Therapeutics) is a biopharmaceutical company that focuses on developing medicines for neurological and psychiatric conditions. It is investigating its lead product candidate KarXT, an oral modulator of muscarinic receptors for the treatment of schizophrenia, negative and cognitive symptoms of schizophrenia and Alzheimer’s disease. The company's other pipeline products include KAR-2618, KAR-401, KAR-501, KAR-201 and KAR-301. Its lead product candidate combines xanomeline, a novel muscarinic agonist that stimulates muscarinic receptors in the central nervous system. Karuna Therapeutics is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
99 High Street, 26th Floor, Boston, Massachusetts, 02110
Website
karunatx.com
Telephone
1 857 4492244
No of Employees
339
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
KRTX (NASD)
Revenue (2022)
$654,000
-93.9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-56.9%
(2022 vs 2021)
Market Cap*
$12.6B
Net Profit Margin (2022)
XYZ
-2,452.5%
(2022 vs 2021)
* As of and is in US$
Karuna Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Karuna Therapeutics |
| KarXT: Schizophrenia, Alzheimer’s Disease | |
| KAR-2618 | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In December, the company entered an agreement to be acquired by Bristol Myers Squibb for US$14 billion. |
| 2023 | Regulatory Approval | In November, the company received the US Food and Drug Administration approval for its New Drug Application for KarXT (xanomeline-trospium) for the treatment of schizophrenia in adults. |
| 2023 | Others | In September, the company announced the submission of a New Drug Application to the US Food and Drug Administration for KarXT (xanomeline-trospium) to treat schizophrenia. |
Competitor Comparison
| Key Parameters | Karuna Therapeutics Inc | Pfizer Inc | Novartis AG | Eli Lilly and Co | Boehringer Ingelheim International GmbH |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United States of America | Germany |
| City | Boston | New York | Basel | Indianapolis | Ingelheim am Rhein |
| State/Province | Massachusetts | New York | - | Indiana | Rheinland-Pfalz |
| No. of Employees | 339 | 88,000 | 76,057 | 43,000 | 53,000 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Bill Meury | President; Chief Executive Officer; Director | Executive Board | - | - |
| Jason Brown | Chief Financial Officer | Senior Management | 2023 | - |
| Andrew Miller | Chief Operating Officer | Senior Management | 2018 | 41 |
| Stephen Brannan | Chief Medical Officer | Senior Management | 2017 | 66 |
| William P. Kane | Chief Commercial Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward